Published by Josh White on 24th June 2024
(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients with metastatic colorectal cancer (CRC).
URL: http://www.digitallook.com/dl/news/story/34381948/...